What question did this study set out to answer?

To analyze real-world data on the outcomes of patients diagnosed with de novo secondary central nervous system lymphoma over two decades.

December 8, 2025Blood

De novo secondary central nervous system lymphoma: A real-world cohort study over two decades

View Full Paper

Ask AI

Bookmark

Authors

Cohort study reveals comparable survival in patients treated for de novo secondary CNS lymphoma, indicating complexity in treatment choice.

To analyze real-world data on the outcomes of patients diagnosed with de novo secondary central nervous system lymphoma over two decades.
Reviewed data from a tertiary cancer institute in Singapore between 1998 and 2024.
Included 66 patients diagnosed with SCNSL from a larger cohort of B-cell and T/NK-cell lymphoma patients.
Assessed treatment types, systemic and CNS-targeting regimens, and survival outcomes.
Median overall survival was 22.4 years with a 75.4% five-year OS rate.
Median progression-free survival was not reached, with a 58.4% five-year PFS rate.
No significant differences in OS and PFS based on CNS-targeting treatment types.

Poon et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Cohort study reveals comparable survival in patients treated for de novo secondary CNS lymphoma, indicating complexity in treatment choice.